Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnetic pulses to the brain may ease fibromyalgia pain and help you walk better

NCT ID NCT07685379

Symptom relief Sponsor: Institute of Rheumatology, Serbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique, can reduce pain, fatigue, and mood problems while improving walking in adults with fibromyalgia. Participants receive either real rTMS or a sham version to see if the active treatment leads to real improvements. The study focuses on both symptoms and everyday physical function, like walking while doing another task.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive transcranial magnetic stimulation (rTMS)
What this could lead to
If it works, this could offer a non-drug option to ease pain, fatigue, and walking difficulties in people with fibromyalgia.
What could go wrong
This is a small, early-stage study with 30 participants. The sham control helps rule out placebo effects, but results may not apply to everyone with fibromyalgia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Sep 2021

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of fibromyalgia based on the revised 2016 American College of Rheumatology criteria. 2. A Visual Analogue Scale pain score of at least 4, with pain present for more than 3 months before inclusion in the study. 3. Pain resistant to standard analgesics, including paracetamol, nonsteroidal anti-inflammatory drugs, and low-potency opioids, administered at full therapeutic doses. 4. If receiving treatment for fibromyalgia, participants had to be on a stable dose for more than 1 month before inclusion in the study. 5. No previous treatment with repetitive transcranial magnetic stimulation. Exclusion Criteria: 1. Inability to provide informed consent. 2. Other chronic conditions, diseases, or disorders that may cause diffuse pain, such as endocrine or metabolic diseases. 3. Other degenerative, orthopedic, or surgical diseases of the musculoskeletal system that significantly affect gait, including the use of crutches or a walking cane. 4. Presence of a chronic inflammatory rheumatic disease. 5. Presence of a systemic autoimmune disease. 6. Primary psychiatric diagnosis, including previously diagnosed severe depressive disorder, generalized anxiety disorder, or psychosis. 7. Psychoactive substance abuse. 8. Neurological diseases that have caused or may cause cognitive or motor deficits. 9. Specific conditions such as active infections, malignancy, osteoporosis with high fracture risk, fractures, and similar conditions. 10. Contraindications to repetitive transcranial magnetic stimulation, including epilepsy, central nervous system trauma, brain surgery, intracranial hemorrhage, implanted pacemaker or other metal implant, pregnancy, or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibromyalgia syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fibromyalgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fibromyalgia syndrome

Contacts and locations

Locations

  • Institute of Rheumatology

    Belgrade, 11000, Serbia

More trials for these conditions

Other studies related to the condition(s) this trial covers.